Immunoprecise Antibodies Ltd Net Asset Quality Index
Immunoprecise Antibodies Ltd net asset quality index. Immunoprecise Antibodies Ltd (IPA) has a Net Asset Quality Index of 53.2% as of April 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $44.44 Million minus total liabilities of $20.82 Million yields net assets of $23.63 Million. A higher index indicates a stronger, lower-leverage balance sheet. See shareholders equity of Immunoprecise Antibodies Ltd for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Immunoprecise Antibodies Ltd (1997–2025)
Net asset quality index of Immunoprecise Antibodies Ltd from 1997 to 2025. This chart shows how Immunoprecise Antibodies Ltd's Net Asset Quality Index has evolved across 29 annual periods from 1997 to 2025. As of April 2025, the index stands at 53.2%, representing net assets of $23.63 Million against total assets of $44.44 Million USD. Check IPA strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Immunoprecise Antibodies Ltd Net Asset Quality Index by Year (1997–2025)
Immunoprecise Antibodies Ltd net asset quality index by year from 1997 to 2025. The table below presents the year-by-year Net Asset Quality Index for Immunoprecise Antibodies Ltd from 1997 to 2025, covering 29 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see IPA stock market capitalisation.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 53.2% | $23.63 Million | $44.44 Million | $20.82 Million | ▼ -3.4 pp |
| 2024 | 56.5% | $33.92 Million | $59.99 Million | $26.07 Million | ▼ -17.7 pp |
| 2023 | 74.3% | $57.80 Million | $77.81 Million | $20.01 Million | ▼ -6.2 pp |
| 2022 | 80.5% | $75.28 Million | $93.49 Million | $18.21 Million | ▼ -4.5 pp |
| 2021 | 85.0% | $56.92 Million | $66.96 Million | $10.04 Million | ▲ +29.7 pp |
| 2020 | 55.3% | $15.09 Million | $27.26 Million | $12.18 Million | ▼ -8.4 pp |
| 2019 | 63.7% | $18.07 Million | $28.35 Million | $10.28 Million | ▲ +12.1 pp |
| 2018 | 51.7% | $12.70 Million | $24.58 Million | $11.87 Million | ▼ -27.0 pp |
| 2017 | 78.7% | $3.09 Million | $3.93 Million | $836.91K | ▲ +12.9 pp |
| 2016 | 65.8% | $908.26K | $1.38 Million | $472.15K | ▲ +517.9 pp |
| 2015 | -452.2% | $-208.52K | $46.12K | $254.64K | ▼ -338.9 pp |
| 2014 | -113.3% | $-161.21K | $142.29K | $303.50K | ▲ +318.2 pp |
| 2013 | -431.5% | $-215.66K | $49.97K | $265.63K | ▼ -302.9 pp |
| 2012 | -128.6% | $-119.89K | $93.22K | $213.10K | ▼ -187.6 pp |
| 2011 | 59.0% | $158.40K | $268.61K | $110.21K | ▼ -39.3 pp |
| 2010 | 98.2% | $5.43 Million | $5.53 Million | $97.87K | ▲ +0.4 pp |
| 2009 | 97.8% | $6.78 Million | $6.93 Million | $150.84K | ▼ -1.4 pp |
| 2008 | 99.3% | $5.12 Million | $5.16 Million | $37.46K | ▲ +6.4 pp |
| 2007 | 92.9% | $5.43 Million | $5.84 Million | $413.69K | ▼ -3.7 pp |
| 2006 | 96.6% | $3.91 Million | $4.05 Million | $138.62K | ▼ -2.3 pp |
| 2005 | 98.9% | $4.23 Million | $4.28 Million | $47.18K | ▲ +2.4 pp |
| 2004 | 96.5% | $1.39 Million | $1.44 Million | $49.92K | ▼ -0.2 pp |
| 2003 | 96.7% | $867.54K | $897.07K | $29.53K | ▲ +18.1 pp |
| 2002 | 78.7% | $691.56K | $879.28K | $187.72K | ▲ +56.0 pp |
| 2001 | 22.6% | $262.24K | $1.16 Million | $896.75K | ▼ -74.9 pp |
| 2000 | 97.5% | $396.53K | $406.64K | $10.11K | ▼ -0.3 pp |
| 1999 | 97.8% | $1.62 Million | $1.66 Million | $35.78K | ▲ +0.1 pp |
| 1998 | 97.7% | $2.86 Million | $2.93 Million | $67.39K | ▲ +4.1 pp |
| 1997 | 93.6% | $3.63 Million | $3.88 Million | $250.04K | — |